Table 1.
Patient Demographics and Disease Characteristics (N = 83)
| Age at time of biologic initiation, y | 36.8 (27.7–47.4) |
| Pouch duration at time of biologic initiation, y | 3.76 (1.3–7.0) |
| Sex | |
| Male | 49 (59.0) |
| Female | 34 (41.0) |
| Tobacco use | |
| Former | 11 (13.3) |
| Current | 4 (4.8) |
| Never | 68 (81.9) |
| Precolectomy biologic typea | 44 (53.0) |
| Infliximab | 36 (81.8) |
| Adalimumab | 7 (15.9) |
| Golimumab | 1 (2.23) |
| Precolectomy immunomodulator use | 49 (59.0) |
| Post-IPAA biologic use indication | |
| CDL pouch inflammation | 64 (77.1) |
| Chronic antibiotic refractory pouchitis | 19 (22.9) |
| Post-IPAA biologic type | 83 (100) |
| Infliximab | 24 (28.9) |
| Adalimumab | 43 (51.8) |
| Vedolizumab | 7 (8.4) |
| Ustekinumab | 6 (7.2) |
| Certolizumab | 3 (3.6) |
| Post-IPAA immunomodulator use | 18 (21.7) |
| Post-IPAA immunomodulator discontinuation | 36 (73.5) |
| Length of follow-up, y | 3.0 (1.5–5.0) |
| Clinical remission | 30 (36.1) |
| CDL pouch inflammation | 21 (70) |
| Chronic pouchitis | 9 (30) |
| Pouch failure | 16 (19.3) |
| CDL pouch inflammation | 12 (75) |
| Chronic pouchitis | 4 (25) |
NOTE. Values are median (interquartile range) or n (%).
CDL, Crohn’s disease–like; IPAA, ileal pouch anal anastomosis.
a
Two patients were on 2 biologics precolectomy, both pre- and postoperative biologics were within a different class.